Jorge Conde and Julie Yoo discuss the unique challenges of building a software company in healthcare, including regulations, market dynamics, and barriers to entry. They also explore the importance of balancing software and human services, data analysis, timing, achieving product-market fit, and navigating regulatory issues and incumbents in the industry.

Explore the past and future of cancer treatment with guests Gary Reedy, CEO of the American Cancer Society, Jonathan Lim, CEO of Erasca, and Jorge Conde, a16z general partner. Topics include the history of cancer treatment, the importance of screening and early detection, future therapies, and preventing cancer.

Marc Andreessen and Jorge Conde discuss the impact of COVID-19 on society and healthcare, including the need for innovation, a pandemic warning system, and measuring output. They explore the similarities between bio-pharma and venture capital, the importance of effective vaccines and telemedicine, and the urgency of rapid building and increased manufacturing capacity for a better future.

Playing out against the backdrop of a global pandemic (including recent massive surges in regions around the world) is the news that came out a week ago that a candidate "malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal”. While the findings are still in preprint with The Lancet, the resulting buzz and phrases quoted included everything from “unprecedented”, “groundbreaking work”, and “very exciting” to “high expectations”, “highly effective”, and “a hugely significant extra weapon”... A "weapon" in the war against malaria that is -- a disease that is estimated to cause over 400,000 deaths each year globally, and predominantly in children under the age of five.So in this special 2x explainer episode of 16 Minutes (also running on the a16z Podcast), we -- Rajeev Venkayya of Takeda Pharmaceuticals, a16z bio general partner Jorge Conde, and Sonal Chokshi -- dig into what's hype/ what's real about this news, beyond the headlines and beyond the buzz. What does the data tell us, what does the current study phase mean, and what's left to get to widespread, real-world use? How does this candidate vaccine (R21 from Jenner Institute/ Oxford University) compare to the other malaria vaccine (RTS,S from GlaxoSmithKline)? How do, and don't, advances in and around COVID vaccines play here? And why has it been so hard to develop vaccines for this particular disease?Because we also cover (as is the premise of the show) where we are on the long arc of innovation... and this is an innovation story that's been nearly a century in the making. 

Rahul Kakkar, John Finn, and Jorge Conde discuss PASTE, a genome editing technique that could make cell therapy more accessible. They explore advancements in genomic medicine, CRISPR technology, and focus on genetic diseases of the liver and autoimmune diseases. They also touch on challenges in transitioning from research to patients and share anecdotes about facial hair.